An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-74
SponsorYuhan Corporation
About this trial
This Study is to Assess the Efficacy and Safety of Adalloce in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis, An Observational, Prospective Study
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Men and women between the ages of over 19 and under 75 at the time of consent
Patients diagnosed with RA or AS at least 3 months prior to the study registration
Patients who are scheduled to be prescribed Adalloce according to the doctor's opinions
Patients who have never received Adalloce
Disqualifiers
Patients with hypersensitivity to this drug or its components
Patients with active tuberculosis or other severe infection such as sepsis or opportunistic infection
Patients with moderate to severe heart failure (NYHA class III/IV)
Patients who are judged to be inappropriate for Adalloce administration according to the approved conditions
Trial population
Those diagnosed with RA or AS
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Changes in quality of life (EQ-5D-5L) scores at 52 weeks from baseline in patients with RA and AS
Time frame
52weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov